<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/FB881F8E-46C6-4DAE-897E-039EE3F02C7D"><gtr:id>FB881F8E-46C6-4DAE-897E-039EE3F02C7D</gtr:id><gtr:name>Biotoolomics Limited</gtr:name><gtr:address><gtr:line1>11 Taylor Street
Consett</gtr:line1><gtr:city>Durham</gtr:city><gtr:postCode>DH8 5RQ</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FB881F8E-46C6-4DAE-897E-039EE3F02C7D" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>FB881F8E-46C6-4DAE-897E-039EE3F02C7D</gtr:id><gtr:name>Biotoolomics Limited</gtr:name><gtr:address><gtr:line1>11 Taylor Street
Consett</gtr:line1><gtr:city>Durham</gtr:city><gtr:postCode>DH8 5RQ</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>250000.0</gtr:offerGrant><gtr:projectCost>653150.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6BAA32D3-0592-4662-8707-B8FF49287B99"><gtr:id>6BAA32D3-0592-4662-8707-B8FF49287B99</gtr:id><gtr:firstName>Unknown</gtr:firstName><gtr:otherNames>Unknown</gtr:otherNames><gtr:surname>Unknown</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=730005"><gtr:id>12334318-699A-4112-913F-530EA4D63C66</gtr:id><gtr:title>Negative Chromatography Technology for Cost Effective manufacturing of Antibody Biopharmaceuticals</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Legacy RDA Grant for R&amp;D</gtr:grantCategory><gtr:grantReference>730005</gtr:grantReference><gtr:abstractText>BioToolomics Ltd is a life science company offering cutting-edge solutions to the
cost-effective purification of biopharmaceutical drugs.
The project is tilted &amp;quot;Negative chromatography technology for the cost-effective
manufacturing of antibody biopharmaceuticals&amp;quot;. In simple term, according to this
technology, an antibody drug produced in cell culture broth is purified by total
removal of its surrounding impurities with our selective but inexpensive
chromatography media. In contrast, conventional purification technology directly
captures antibody drugs with expensive and capacity-limited Protein-A affinity media.
With the strong support of two previous Research Grants, BioToolomics has
successfully identified the know-hows in making inexpensive process
chromatography base matrix, disposable columns and selective mixed-mode
ligands. BioToolomics has built up a large library of mixed-mode chromatography media.
By coupling the selective mixed-mode ligands to the inexpensive base matrix, very innovative process chromatography products in a ready-to-use disposable format could be developed and deployed in totally new and cost-saving antibody manufacturing processes.
Novartis (one of the top five pharmaceutical giants) has agreed to collaborate with
BioToolomics to evaluate the technology. We expect to form more collaborations with
other big pharmaceutical companies. Therefore, it is the logical decision for
BioToolomics to develop the technology towards the market-ready status to harvest
its great commercial potential.</gtr:abstractText><gtr:fund><gtr:end>2014-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2010-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>250000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">730005</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>